Fractalkine: A cellular link between adipose tissue inflammation and vascular pathologies

Diabetes

Volumn 60, Issue 5, 2011, Pages 1380-1382

  Cefalu, William T ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FRACTALKINE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ADIPOSE TISSUE; ANGINA PECTORIS; APOPTOSIS; ATHEROSCLEROSIS; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; ENDOTOXEMIA; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LEUKOCYTE; METABOLIC SYNDROME X; MONOCYTE; MONONUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR TISSUE; WAIST CIRCUMFERENCE;

ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; CHEMOKINE CX3CL1; HUMANS; OBESITY;

EID: 79959427550     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0239     Document Type: Note

References (15)

1. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science 1993;259:87-91 (Pubitemid 23036092)
2. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993;268:26055-26058
3. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-361 (Pubitemid 38508511)
4. Vernochet C, Peres SB, Farmer SR. Mechanisms of obesity and related pathologies: transcriptional control of adipose tissue development. FEBS J 2009;276:5729-5737
5. Galgani J, Ravussin E. Energy metabolism, fuel selection and body weight regulation. Int J Obes (Lond) 2008;32(Suppl. 7):S109-S119
6. Bouchard C. Gene-environment interactions in the etiology of obesity: defining the fundamentals. Obesity (Silver Spring) 2008;16(Suppl. 3):S5-S10
7. Shah R, Hinkle CC, Ferguson JF, et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 2011;60:1512-1518
8. Maegdefessel L, Schlitt A, Pippig S, et al. Patients with insulin-dependent diabetes or coronary heart disease following rehabilitation express serum fractalkine levels similar to those in healthy control subjects. Vasc Health Risk Manag 2009;5:849-857
9. White GE, Tan TC, John AE, Whatling C, McPheat WL, Greaves DR. Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res 2010;85:825-835
10. Ikejima H, Imanishi T, Tsujioka H, et al. Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ J 2010;74:337-345
11. Umehara H, Tanaka M, Sawaki T, et al. Fractalkine in rheumatoid arthritis and allied conditions. Mod Rheumatol 2006;16:124-130 (Pubitemid 43871686)
12. Liu H, Jiang D, Zhang S, Ou B. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. Cardiovasc Drugs Ther 2010;24:17-24
13. Kimouli M, Miyakis S, Georgakopoulos P, Neofytou E, Achimastos AD, Spandidos DA. Polymorphisms of fractalkine receptor CX3CR1 gene in patients with symptomatic and asymptomatic carotid artery stenosis. J Atheroscler Thromb 2009;16:604-610
14. Apostolakis S, Amanatidou V, Papadakis EG, Spandidos DA. Genetic diversity of CX3CR1 gene and coronary artery disease: new insights through a meta-analysis. Atherosclerosis 2009;207:8-15
15. Debette S, Bevan S, Dartigues JF, et al. Fractalkine receptor/ligand genetic variants and carotid intima-media thickness. Stroke 2009;40:2212-2214